Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer
Year: 2017
Type: article
Author: Lynda McGahan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: palbociclib, fulvestrant, CDK4/6 inhibitors, hormone receptor-positive breast cancer, HER2-negative breast cancer, metastatic breast cancer, progression-free survival, endocrine therapy resistance, retinoblastoma protein phosphorylation, cell cycle regulation, quality of life, adverse events, drug safety, drug efficacy, aromatase inhibitors
Open Access status: closed
OpenAlex ID: W2581287805
